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2Abstract
The association of lipophilic statins with plasma lipoproteins in the presence of disturbed acid-base
balance can modify the pharmacokinetics and tissue distribution of these drugs, resulting in alteration
in their efficacy and toxicity profiles. The purpose of this study is to elucidate the role of
hyperlipidaemia alone or in combination with acidosis/alkalosis in the development and potentiation
of statin-induced myotoxicity. Statins association with plasma lipoproteins was examined under
conditions of physiological and altered pH levels. The effect of this association on cellular uptake and
myotoxicity of statins was also assessed at different pH levels using C2C12 cells that overexpress
lipoprotein lipase. Lipophilic simvastatin displayed considerable association with the non-polar
lipoprotein fractions (triglyceride-rich lipoproteins and Low-density lipoprotein). This association
contributed to increased cellular uptake of simvastatin by C2C12 cells through lipoprotein lipase-
mediated process, resulting in enhanced muscle toxicity in hyperlipidaemic conditions. Furthermore, a
combination of low pH environment (representing acidosis) and hyperlipidaemia increased the
association of simvastatin with plasma lipoproteins causing potentiation of cellular uptake and
myotoxicity of this drug. Comorbidities such as hyperlipidaemia, especially when coincident with
acidosis, can enhance statin-associated muscle toxicity, and therefore require extra caution by
prescribing clinicians. Hydrophilic rather than lipophilic statins could be a preferable choice in this
patient population.
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Chemical compounds studied in this article:
Simvastatin lactone (PubChem CID: 54454); Simvastatin hydroxy acid (PubChem CID: 64718);
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lipoprotein; LPDP, lipoprotein-deficient plasma; mLPL, mouse lipoprotein lipase; MTT, thiazolyl
blue tetrazolium bromide; MSCV, murine stem cell virus; SV-LDL, simvastatin-loaded low-density
lipoprotein; SV-Sol, simvastatin solution; SV-TRL, simvastatin-loaded triglyceride-rich lipoproteins;
TRL, triglyceride-rich lipoproteins.
41. Introduction
Statins are essential pharmacotherapy for patients with ischemic heart disease and
dyslipidaemia (Perk et al., 2012; Stone et al., 2014). However, these drugs have the potential to cause
serious side effects such as muscle-related toxicity and hepatotoxicity. Statins are classified into
hydrophilic or lipophilic compounds based on their physicochemical properties and tissue selectivity
(Hamelin and Turgeon, 1998; Joshi et al., 1999). These drugs are available either as lactone or
hydroxy acid forms. In general, the lactone forms of statins are more lipophilic, and indeed, more
myotoxic than the corresponding hydroxy acid forms owing to their lipophilicity (Schirris et al., 2015;
Skottheim et al., 2008).
It has been estimated that, in clinical practice, about 10% of patients receiving high-dosage
statin therapy develop statin-induced myotoxicity (Bruckert et al., 2005). The exact mechanism of
statin-induced myotoxicity remains largely unclear. Comorbidities including conditions such as
hepatic or renal failure, hypothyroidism, and diabetes mellitus are among the most important risk
factors that have been shown to predispose patients to statin-induced myotoxicity (Taha et al., 2014).
We have previously reported that disturbances in acid-base balance, such as acidosis or alkalosis,
could influence the toxicity profile of statins. Acidosis increases the proportion of lipophilic lactone
form, promotes accumulation of statins in skeletal muscle cells and enhances statin-induced
myotoxicity in vitro (Taha et al., 2016).
Association with plasma lipoproteins has been shown to modify the pharmacokinetics, tissue
distribution and pharmacological activity of lipophilic drugs (Wasan and Cassidy, 1998; Yeganeh and
McLachlan, 2002). For example, increased association with low-density lipoproteins (LDL) has been
linked to higher nephrotoxicity of amphotericin B and cyclosporine (Luke et al., 1992; Wasan and
Conklin, 1997).
Transient elevation in triglyceride-rich lipoproteins (TRL), mainly chylomicrons, occurs
following the ingestion of a high-fat meal (Gershkovich and Hoffman, 2007). These lipoproteins are
the major carriers of lipids in the systemic circulation, and can also serve as potential carriers for
lipophilic statins (Simon et al., 1997; Wasan and Cassidy, 1998). Similarly, pathological
hyperlipidaemia is associated with elevated levels of some lipoproteins (very low-density lipoprotein
5[VLDL] and LDL). Lipophilic statins can associate with plasma lipoproteins in the general
circulation, and this, in turn, can facilitate their delivery to peripheral tissues. Lipoprotein lipase
(LPL) present at the surface of the capillary endothelium of cardiac and skeletal muscle and adipose
tissue mediates the hydrolysis of triglycerides within the TRL to fatty acids and monoacylglycerol.
Released free fatty acids are then transported across cell membranes to the tissues of LPL synthesis
and secretion (Wang and Eckel, 2009). This process could be accompanied by an increase in the
uptake of lipoprotein-associated lipophilic statins by the skeletal muscle. In addition, LPL also
mediates the internalisation of LDL into cells as reported in several studies (Obunike et al., 1994;
Rumsey et al., 1992), which could be an additional mechanism of enhanced intracellular accumulation
and toxicity of statins in hyperlipidaemic state. Therefore, the administration of lipophilic statins to
patients with pathological or postprandial hyperlipidaemia could potentially contribute to enhanced
muscle toxicity.
The coincidence of hyperlipidaemia with acidosis could augment the myotoxicity of statins
even further. This is because acidosis, as we have previously demonstrated (Taha et al., 2016),
increases the proportion of lipophilic lactone form of statins in the general circulation and skeletal
muscle. This can contribute to statin-induced muscle toxicity by increasing the association of lactone
form with plasma lipoproteins, and increasing the intracellular concentration of statins by LPL-
mediated mechanism.
Both acidosis and hyperlipidaemia are quite common among statin users. Most patients using
statins have abnormal plasma lipoproteins levels. It is common for clinicians to recommend such
patients to use unsaturated fat and fatty acids such as olive oil for prevention of cardiovascular and
atherosclerotic diseases (Buttar et al., 2005). The use of these oils is associated with transient
elevation in plasma TRL, mainly chylomicrons (Jespersen et al., 2001). In addition, many patients on
statins have multiple co-morbidities such as diabetes mellitus, cardiovascular and renal diseases.
These conditions are risk factors for development of metabolic acidosis (Köse et al., 2014).
To the best of our knowledge, there are no previously reported studies which examined the
influence of hyperlipidaemia, or a combination of hyperlipidaemia and acidosis, on the myotoxic
potential of statins. Therefore, the aim of this study is to assess the effect of hyperlipidaemia alone
6and in combination with acidosis/alkalosis on development and severity of statin-induced
myotoxicity.
2. Materials and methods
2.1. Materials
Simvastatin lactone (99.3%) and pravastatin hydroxy acid sodium (99.4%) were purchased
from Kemprotec Ltd (Lancashire, UK). Pravastatin lactone (98%) and simvastatin hydroxy acid
ammonium salt (98.0%) were obtained from Toronto Research Chemicals Inc (Toronto, Canada).
Thiazolyl blue tetrazolium bromide (MTT) was purchased from Alfa Aesar (Lancashire, UK).
Dulbecco’s modified eagle medium (42430025-DMEM, high glucose, HEPES without sodium
pyruvate) was purchased from GIBCO-Invitrogen. Pooled hyperlipidaemic human plasma was
obtained from Biological Specialty Corporation (Pennsylvania, USA). LPL activity fluorometric
assay kit and total cholesterol and cholesteryl ester colorimetric assay kit were purchased from T/A
Source BioScience Ltd (Wiltshire, UK). Microsep™ advance centrifugal device with Omega™
membrane was obtained from VWR International Ltd (Leicestershire, UK). Triglyceride reagent, free
glycerol reagent, and glycerol standard were obtained from Sigma-Aldrich (Dorset, UK). PierceTM
lactate dehydrogenase (LDH) Cytotoxicity Assay kit was purchased from Thermo Fisher Scientific
(Loughborough, UK). All other reagents were of high-performance liquid chromatography (HPLC)
grade.
2.2. In silico prediction of statins association with chylomicrons
A previously reported in silico model was applied to predict the degree of association of
simvastatin lactone, simvastatin hydroxy acid, pravastatin lactone and pravastatin hydroxy acid with
chylomicrons (Gershkovich et al., 2009). The model relies on physicochemical parameters calculated
using ACD/I-Lab (Advanced Chemistry Development Inc.) for each compound (Supplementary Table
1).
72.3. Association of statins with plasma-derived human chylomicrons
Chylomicron fractions were obtained from human plasma following induction of transient
postprandial hypertriglyceridaemia. The study was approved by the Faculty of Medicine and Health
Sciences Research Ethics Committee, Queens Medical Centre, Nottingham University Hospitals
(BT12102015 CBS SoP). Three healthy male volunteers (25-35 years old) were recruited for this
study after giving informed consents. Participants were instructed not to use any over the counter
medication for one-week prior to the study. Following 12 h overnight fasting, participants had long-
chain triglyceride-rich breakfast (full English breakfast or olive oil-fried eggs). Three to four hours
following the meal [expected time of peak plasma chylomicron levels (Cohn et al., 1988; Cohn et al.,
1989)] blood samples (30 ml) were collected and plasma was separated by centrifugation (800 g, 10
min, 15°C). Chylomicrons were separated from human plasma by density gradient ultracentrifugation
using Sorvall® Discovery 100 SE Ultracentrifuge (TH-641 Rotor, 35 min, 274,044 g, 15oC) as
described previously (Gershkovich et al., 2009; Gershkovich and Hoffman, 2005). The top 1 ml,
white milky layer representing the chylomicron fraction was collected, and triglyceride content was
measured using triglyceride colorimetric kit. Chylomicrons emulsion was diluted with PBS to a
triglyceride level of 100 mg/dl and the emulsion was kept at 4°C pending association experiments (˂ 
24 h).
The uptake of simvastatin lactone, simvastatin hydroxy acid, pravastatin lactone and pravastatin
hydroxy acid by human chylomicrons was evaluated as previously described (Gershkovich et al.,
2009; Gershkovich and Hoffman, 2005). All incubation experiments were carried out at physiological
pH 7.4 in addition to pH levels that correspond to acidosis (pH 6.8) and alkalosis (pH 7.8) as describe
previously (Taha et al., 2016). The selection of this range was based on extreme but clinically relevant
disturbances in acid-base balance that are encountered in patients with long-term diuretics use
(Tripathy, 2009), prolonged vomiting (Galla, 2000), diabetic ketoacidosis (Wathen and Starkey,
1986), lactic acidosis (Winocour et al., 1989), renal tubular acidosis (Kraut and Kurtz, 2005),
hypovolemic shock (Zimmer, 2014), and ethylene glycol intoxication (Lundgaard, 2009). It should be
noted that significant effects of milder plasma pH alterations on statin inter-conversion between
lactone and hydroxy acid forms were also reported in our previous works (Taha et al., 2016).
8Stock solutions of four statins (350 µM) were prepared in propylene glycol and an appropriate
volume of each solution was added to 1 ml of human chylomicron emulsions of different pH to
achieve a final concentration of 1.75 µM. Statins were incubated with chylomicrons at 37oC for 1 h
with constant mixing. Following incubation, statin-loaded chylomicron particles were separated by
density gradient ultracentrifugation (Sorvall® Discovery 100 SE Ultracentrifuge; TH-641 Rotor, 35
min, 274,044 g, 15oC). The top 1 ml was collected and kept at -80oC until analysis. The
concentrations of statins in chylomicron fraction were determined by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) method as described previously (Taha et al., 2016).
2.4. Effect of hyperlipidaemia alone or in combination with acidosis/alkalosis on simvastatin
association with plasma lipoproteins
Both normolipidaemic (total triglyceride 63.0 ± 2.9 mg/dl; cholesterol 134.7 ± 8.9 mg/dl) and
hyperlipidaemic (total triglyceride 448.0 ± 12.1 mg/dl; cholesterol 348.5 ± 15.5 mg/dl) plasmas were
used for the evaluation of simvastatin association with plasma lipoproteins. The pH of plasma samples
was adjusted to achieve physiological pH 7.4, pH 6.8 (acidosis) or pH 7.8 (alkalosis), as described
previously (Taha et al., 2016).
An appropriate volume of simvastatin lactone stock solution was added to 3 ml of
normolipidaemic or hyperlipidaemic human plasma of defined pH to achieve final simvastatin
concentration of 2 µg/ml. Samples were incubated at 37oC for 1 h and lipoprotein fractions were
separated by density gradient ultracentrifugation at 274,044 g for 18 h, as described previously
(Redgrave et al., 1975). The concentrations of simvastatin lactone and hydroxy acid forms found in
individual lipoprotein fractions were determined by LC-MS/MS (Taha et al., 2016). The total
triglyceride and cholesterol levels of hyperlipidaemic plasma, normolipidaemic plasma and individual
lipoprotein fractions were determined by enzymatic methods using commercially available kits.
92.5. Effect of hyperlipidaemia alone or in combination with acidosis/alkalosis on cellular uptake of
lipophilic statin
C2C12 cells that overexpress mouse lipoprotein lipase (mLPL) or human lipoprotein lipase
(hLPL) were used in these studies. Cells transfected with empty vector were used as control. mLPL
and hLPL were cloned into murine stem cell virus (MSCV) mammalian expression vector. To
produce retrovirus for stable overexpression of hLPL and mLPL, 6 µg of each plasmid (mLPL, hLPL,
and the empty MSCV vector) was combined with a transformation mixture containing 3 µg pCL-Eco
packaging plasmid, 2 µg VSVG pseudotyping plasmid, and 33 µl Lipofectamine 2000 (Invitrogen) in
1 ml Opti-MEM (Invitrogen). The transformation cocktails were added to Phoenix 293T retroviral
packaging cells grown to ~85% confluence. Virus-containing supernatant was then harvested from the
packaging cells 48 h following transfection. C2C12 cells at P2 were then grown to 30% confluence
and incubated with the virus-containing supernatant along with 10 μg/ml polybrene. The cells were 
incubated with the virus for 24 h followed by a medium change and a 24 h recovery period.
C2C12 cells were cultured in a humidified environment of 5% CO2 at 37°C and maintained
sub-confluent (70-80%) by growing in DMEM medium supplemented with 10% fetal bovine serum,
1% L-glutamine and 1% penicillin-streptomycin antibiotic mixture. Myogenic differentiation was
induced by growing the cells in differentiation medium containing 2% horse serum. The cells were
cultured over a period of 4 to 6 days to allow complete differentiation and the medium was replaced
every 24 h (Masilamani et al., 2014).
The effect of hyperlipidaemia alone and in combination with acidosis/alkalosis on cellular
uptake of simvastatin was tested by incubating C2C12 cells with simvastatin-loaded lipoprotein
fractions at pH relevant to physiological conditions, acidosis, and alkalosis. Simvastatin-loaded
lipoprotein fractions were obtained by incubating the drug with hyperlipidaemic human plasma of
different pH. An appropriate volume of simvastatin lactone stock solution prepared in propylene
glycol (9 mg/ml) was added to hyperlipidaemic human plasma of defined pH (6.8, 7.4 or 7.8) to
achieve a final concentration of 90 μg/ml. Samples were incubated at 37oC for 1 h. Lipoprotein
fractions were then separated by density gradient ultracentrifugation as described above. After
separation, individual lipoprotein fractions were transferred into Microsep™ Advance Centrifugal
10
Device with Omega™ membrane for removal of potassium bromide salt used in lipoproteins
separation. Aliquots were used to determine the concentration of simvastatin in individual lipoprotein
fractions by LC-MS/MS. The remaining volume of lipoprotein fractions was used to perform the
uptake study by undifferentiated and differentiated C2C12 cells that overexpress mLPL, hLPL, and
control cells transfected with empty vector. Cells were cultured in 10 cm dishes at a density of
2×105/ ml and allowed to attach for 24 h or to differentiate for 4 days by switching to differentiation
medium containing 2% horse serum. Before starting the uptake study, the medium was replaced with
a fresh medium of different pH and the cells were allowed to equilibrate for 10 min. The uptake
studies were initiated by applying simvastatin-loaded lipoprotein fractions (simvastatin-loaded
triglyceride-rich lipoproteins [SV-TRL] or simvastatin-loaded low-density lipoprotein [SV-LDL]) to
the cells and the cells were incubated for 3 h at 37oC and 5% CO2. Control cells were treated with a
similar concentration of simvastatin applied as a solution (SV-Sol) directly on the cells without
lipoprotein fractions. Simvastatin uptake was terminated by suctioning off the DMEM containing the
lipoprotein fractions and the cells were harvested by trypsinization and resuspended in 200 µl
phosphate buffer saline (PBS, pH 7.4). The intracellular concentrations of both simvastatin lactone
and the hydroxy acid form were determined in cell suspension using LC-MS/MS, and the results were
corrected for cellular protein contents as described previously (Taha et al., 2016). LPL enzyme
activity was determined using commercially available kit by following the manufacturer’s
instructions.
2.6. Effect of hyperlipidaemia alone or in combination with acidosis/alkalosis on cytotoxicity of
simvastatin
The effect of simvastatin association with plasma lipoproteins on the viability of C2C12 cells
was evaluated by MTT and LDH cytotoxicity assays. Undifferentiated and differentiated C2C12 cells
that overexpress mLPL or hLPL, and control cells were treated either with simvastatin-loaded
lipoproteins factions or with simvastatin applied directly in solution at concentrations identical to
those achieved within the lipoprotein fractions. The incubation was performed in culture medium of
physiological pH 7.4. In order to assess the combined effect of elevated plasma lipoprotein levels and
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medium pH alteration on the cytotoxicity of simvastatin, C2C12 cells were also incubated in culture
medium of modified pH (6.8 and 7.8).
For MTT assay, cells were cultured at a density of 4,000 cells/ well in 96-well plates and
allowed to attach for 24 h or to differentiate for 4 days. Before starting the treatment, the medium was
replaced by a fresh one of defined pH and the cells were allowed to equilibrate for 10 min. C2C12
cells were exposed to different concentrations of simvastatin either loaded into lipoprotein fractions
(SV-TRL or SV-LDL) or applied directly in solution for 72 h, and the metabolic activity of the cells
was measured using the MTT assay. Control cells were treated with blank lipoprotein fractions
without simvastatin. Results were expressed as percentage of the control and the half-maximal
inhibitory concentrations (IC50) values were calculated using Prism 6 (GraphPad Software Inc).
Membrane integrity of C2C12 cells was assessed by means of LDH assay. The test was
performed at the final simvastatin concentrations that were obtained in the lipoprotein fractions after
desalting process. Cells were cultured and treated as described above. Undifferentiated cells were
treated for 72 h, whereas differentiated cells were maintained for 24 h and LDH assay was performed
according to manufacturer’s instructions.
2.7. Statistical analysis
Data were expressed as mean ± standard error (SE). Statistical differences between groups were
determined by one-way or two-way ANOVA, followed by Tukey’s or Fisher's least significant
difference (LSD) post hoc tests, as appropriate using Prism 6 (GraphPad Software Inc). Pearson’s
correlation coefficient (r) was used to describe the relationship between the amount of simvastatin-
associated with plasma lipoproteins and the triglyceride or cholesterol contents of individual




3.1. In silico prediction of statins association with chylomicrons
The predictive values of statins association with chylomicrons obtained using the in silico
model are presented in Supplementary Table 1. Simvastatin hydroxy acid, pravastatin lactone and
pravastatin hydroxy acid showed no predicted association with chylomicrons. Simvastatin lactone was
the only form that showed a considerable predicted affinity to chylomicrons (9.08%).
3.2. Association of statins with plasma-derived isolated chylomicrons
Similar to in silico prediction, simvastatin hydroxy acid, pravastatin lactone and pravastatin
hydroxy acid showed no association with chylomicrons ex vivo. These statins have not been selected
for subsequent studies because of the lack of association of these compounds with chylomicrons (as
demonstrated by the in silico and ex vivo models over different pH levels), as well as low cytotoxicity
observed with these statins as described in our previous study (despite the fact that pH affects the
conversion of these statins between the hydroxy acid and lactone forms) (Taha et al., 2016). The
results of association of simvastatin lactone with plasma-derived isolated chylomicrons are
summarised in Fig. 1. At physiological pH, the association of simvastatin with chylomicrons was
found to be 18.5%. When association was tested at different pH levels, significant differences were
found at alkaline pH. The association value was the lowest in alkaline condition (14.2%) while neutral
pH and acidic pH resulted in higher association values (18.5% and 19.3%, respectively). No
simvastatin lactone was detected in the upper 1 ml layer of the ultracentrifuge tube (corresponding to
chylomicron fraction) in the control (PBS) samples.
3.3. Effect of hyperlipidaemia alone or in combination with acidosis/alkalosis on simvastatin
association with plasma lipoproteins
The distribution of simvastatin lactone into different lipoprotein fractions from hyperlipidaemic
and normolipidaemic human plasma is presented in Fig. 2. Simvastatin lactone showed considerably
higher association with the non-polar lipoproteins fractions [TRL (including both chylomicrons and
VLDL) and LDL] extracted from hyperlipidaemic plasma, compared to its association with
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lipoproteins from normolipidaemic plasma. On the other hand, more simvastatin associated with high-
density lipoprotein (HDL) of normolipidaemic plasma compared to hyperlipidaemic plasma.
To investigate the factors influencing simvastatin association with plasma lipoproteins,
cholesterol and triglyceride levels were determined in each lipoprotein fraction from hyperlipidaemic
and normolipidaemic plasma samples (Supplementary Fig. 1 and 2, respectively). In addition, the
correlations between the amount of simvastatin recovered in individual lipoprotein fractions and the
amount of triglyceride and cholesterol present in each fraction were examined (Supplementary Fig. 3
and 4). Positive correlations (p < 0.01) were observed between the amount of triglyceride or
cholesterol and the amount of simvastatin-associated with TRL and LDL. On the other hand, negative
correlations (p < 0.01) were found between the amounts of simvastatin recovered in HDL and
triglyceride or cholesterol contents of this fraction. As expected, the correlations between the
triglyceride or cholesterol contents of lipoprotein-deficient plasma (LPDP) fraction and the amount of
simvastatin recovered within this fraction were non-significant (p > 0.05).
Overall, simvastatin association with different plasma lipoproteins in hyperlipidaemic plasma
was greater at acidic pH compared to physiological and alkaline pH. At acidic pH, more than 50% of
simvastatin distributed to different lipoprotein fractions in hyperlipidaemia plasma (20% in TRL, 20%
in LDL, and 16% in HDL). The remaining simvastatin (less than 50%) appeared in the LPDP fraction.
However, at physiological and alkaline pH, most simvastatin was recovered in the LPDP fraction
(Fig. 2).
Measuring the concentrations of simvastatin lactone and the corresponding hydroxy acid within
each lipoprotein fraction provided a picture of the effect of plasma pH alteration on simvastatin
distribution into different lipoprotein fractions (Supplementary Fig. 5 and 6). At acidic pH, the
majority of simvastatin recovered in lipoprotein fractions was in the lipophilic lactone form. As the
pH increases, more simvastatin lactone starts to convert to the more hydrophilic hydroxy acid form,
resulting in simvastatin redistribution to the more polar LPDP fraction.
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3.4. Effect of hyperlipidaemia alone or in combination with acidosis/alkalosis on cellular uptake of
lipophilic statin
To examine the effect of plasma lipoprotein association on cellular uptake of simvastatin,
C2C12 cells were incubated with simvastatin loaded into lipoprotein fractions (TRL or LDL) or
applied directly as a solution. In addition to physiological pH, uptake study was also conducted at pH
corresponding to acidosis and alkalosis to elucidate the role of hyperlipidaemia and acid-base
imbalance on cellular uptake of simvastatin. Figure 3 shows the total simvastatin (lactone and
hydroxy acid forms combined) taken up by C2C12 cells that overexpress mLPL, hLPL, or control
cells following treatment with simvastatin-loaded TRL. The same amounts of simvastatin were
recovered in undifferentiated cells that have low endogenous LPL expression ability following
treatment either with TRL bound simvastatin or free simvastatin in solution. On the other hand, higher
simvastatin uptake was observed in undifferentiated cells that overexpress mLPL or hLPL upon
treatment with simvastatin-preloaded TRL fractions compared to simvastatin in solution (Fig. 3).
Results of simvastatin uptake by C2C12 cells treated with simvastatin-loaded LDL are shown
in Fig. 4. Undifferentiated C2C12 cells that overexpress mLPL or hLPL showed higher simvastatin
uptake when treated with simvastatin-loaded LDL compared to their treatment with simvastatin
solution (Fig. 4). No significant differences in simvastatin uptake was detected in control
undifferentiated C2C12 cells following treatment with either simvastatin-loaded LDL or simvastatin
applied directly in solution at physiological and alkaline pH. However, more simvastatin was found in
these cells under acidic conditions when treated with simvastatin solution compared to simvastatin-
loaded LDL (Fig. 4). Overall, higher cellular uptake was observed when undifferentiated cells were
treated with simvastatin-loaded LDL compared to their treatment with simvastatin-loaded TRL (Fig. 3
and 4).
Differentiated C2C12 cells that overexpress mLPL or hLPL showed higher simvastatin uptake
upon treatment with simvastatin-loaded lipoprotein fractions compared to free simvastatin solution. It
is worth noting that differentiated control cells (transfected with empty vector) also showed higher
simvastatin uptake when treated with simvastatin-loaded LDL compared to undifferentiated cells (Fig.
4).
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A remarkable point is that the amounts of simvastatin found in differentiated cells were several-
fold higher than in undifferentiated cells following treatment with simvastatin associated with
lipoprotein fractions (Supplementary Fig. 7 and 8). The data also show that maintaining both
undifferentiated and differentiated cells in acidic medium further increases the cellular uptake of
simvastatin whether it is bound to lipoprotein fractions or applied as free simvastatin in solution (Fig.
3 and 4).
To illustrate the role of LPL in the cellular uptake of simvastatin-loaded lipoprotein particles,
the activity of the enzyme was measured in the different cell types used in our studies. The activity
was found to be almost three- and two-fold higher in undifferentiated C2C12 cells that overexpress
mLPL or hLPL compared to control cells, respectively. On the other hand, differentiated C2C12 cells
that overexpress mLPL showed higher enzyme activity compared to those expressing hLPL or control
cells (Fig. 5). In addition, differentiated mLPL transfected cells showed 1.5-fold higher LPL activity
compared to undifferentiated cells (Supplementary Fig. 9).
3.5. Effect of hyperlipidaemia alone or in combination with acidosis/alkalosis on cytotoxicity of
simvastatin
The effects of simvastatin association with plasma lipoproteins on the mitochondrial activity of
C2C12 cells were assessed by MTT assay using simvastatin-loaded lipoprotein fractions. The
incubations were performed at physiological pH, in addition to pH levels corresponding to acidosis
and alkalosis, in order to further explore the combined effects of hyperlipidaemia and pH alteration on
the viability of muscle cells. Results from MTT assay over different concentrations of simvastatin-
loaded TRL and LDL fractions are shown in Fig. 6 and 7, respectively. To provide a comparison
between different treatment conditions, the IC50 were calculated, when applicable, for each growth
inhibition-dose curve. The results of cell viability assay showed higher cytotoxicity when C2C12 cells
were treated with simvastatin-loaded lipoprotein fractions compared to cells treated with simvastatin
solution. Furthermore, the inhibitory effect of simvastatin-loaded lipoprotein fractions on cell viability
was more pronounced with cells that overexpress mLPL compared to those expressing hLPL or
control cells. Cells that overexpress hLPL showed moderate response to simvastatin-loaded
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lipoprotein therapy and the IC50 values were in between those overexpressing mLPL or control cells.
Both undifferentiated and differentiated cells were found to be more sensitive to simvastatin when
applied loaded into LDL compared to simvastatin-loaded TRL fractions (Fig. 6 and 7).
Treating undifferentiated or differentiated C2C12 cells with simvastatin in culture medium of
acidic pH resulted in significant reduction in cell viability whether the cells were treated with
simvastatin-loaded lipoprotein fractions or free simvastatin in solution. On the other hand, no
significant reduction in cell viability was observed for cells maintained in alkaline culture medium
following treatment with simvastatin-loaded lipoprotein fractions or simvastatin solution. At this
alkaline pH (7.8), the viability of the cells remained above 50% even after treatment with the highest
dose of simvastatin and therefore it was not possible to calculate the IC50 values under this treatment
condition (Fig. 6 and 7).
Results of LDH release from undifferentiated and differentiated C2C12 cells are shown in Fig.
8. Overall, more LDH was released from these cells when treated with simvastatin-loaded lipoprotein
fractions compared to cells treated with simvastatin solution. The higher LPL enzyme activity in
undifferentiated cells that overexpress mLPL produced an additional increase in LDH release when
treated with simvastatin-loaded TRL. Moreover, treating these cells with simvastatin-loaded LDL
resulted in greater LDH release compared to cells that have low endogenous enzyme activity. Higher
LDH release was observed for cells maintained in acidic culture medium compared to neutral and




Certain comorbidities such as hepatic or renal failure, hypothyroidism, and diabetes mellitus
have been suggested to affect the occurrence and severity of statin-associated muscle symptoms
(Chatzizisis et al., 2010; Reiner, 2014). The current study describes the role of hyperlipidaemia, a
primary disorder for which statins are considered as first choice therapy, in development and
potentiation of statin-induced myotoxicity. An increased association of lipophilic drugs with plasma
lipoproteins in hyperlipidaemic patients can affect drug distribution and toxicity profile (Wasan and
Cassidy, 1998; Yeganeh and McLachlan, 2002). Since acidosis is known to enhance the lipophilicity
of statins (Taha et al., 2016), it is possible that the coexistence of acidosis with hyperlipidaemia could
further augment the myotoxicity of statins. To the best of our knowledge, this is the first work that
elucidates the influence of pathological or postprandial hyperlipidaemia alone or in combination with
acidosis/alkalosis on the development and severity of simvastatin-induced myotoxicity.
4.1. Association of statins with plasma-derived isolated chylomicrons
Results from in silico model for prediction of drug uptake by plasma chylomicrons indicate that
physicochemical properties of statins highly influence their uptake by plasma lipoproteins.
Simvastatin lactone (lipophilic statin) with a high LogD7.4 and low polar surface area showed the
highest association with chylomicrons.
When the association of simvastatin lactone was assessed with human chylomicrons, a
significant pH-dependent trend was observed. Alkaline pH resulted in the lowest association (Fig. 1),
suggesting that in the pathophysiological condition of alkalosis less simvastatin would be able to
associate with plasma lipoproteins. On the other hand, acidosis can result in more simvastatin
becoming associated with plasma lipoproteins.
A greater percentage of simvastatin lactone is expected to associate with chylomicrons upon
entrance into the blood stream especially in the presence of postprandial or pathological
hyperlipidaemia which is often associated with elevated levels of TRL. Such association raises the
possibility of altered therapeutic and toxic response to lipophilic statins.
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4.2. Effect of hyperlipidaemia alone or in combination with acidosis/alkalosis on simvastatin
association with plasma lipoproteins
Hyperlipidaemia can affect the pharmacokinetics and pharmacodynamics of drugs (Procyshyn
et al., 2003). This may occur through due to a shift in binding of lipophilic drug from plasma proteins
to the non-polar lipoprotein fractions such as TRL and LDL (Hamdy and Brocks, 2011).
The concentrations of plasma lipoproteins in the blood can vary significantly among individuals
as a function of diet or disease states. This variability could have significant implications on the fate
of drugs that associate with plasma lipoproteins. In the present study, simvastatin has been shown to
associate with different lipoprotein fractions in hyperlipidaemic and normolipidaemic plasma, and
more significant association with lipoprotein fractions obtained from hyperlipidaemic plasma (Fig. 2).
Several factors have been suggested to influence the extent of drug association with plasma
lipoproteins. Some of these factors are linked to the molecular nature of the compounds such as drug
lipophilicity. Other factors are related to the nature of lipoproteins such as size, total lipid contents or
apolipoprotein components of lipoprotein fractions (Wasan et al., 2008). In the present study,
significant positive correlations were observed between the triglyceride and cholesterol contents of
lipoprotein fractions (TRL and LDL) and the degree of simvastatin association with these fractions
(Supplementary Fig. 3 and 4).
More simvastatin has been shown to associate with plasma lipoproteins at acidic pH compared
to physiological and alkaline pH (Fig. 2). The higher association at acidic pH occurs as a result of
simvastatin’s increased lipophilicity as majority of simvastatin molecules remain in the highly
lipophilic lactone form at low pH (Supplementary Fig. 5 and 6).
4.3. Effect of hyperlipidaemia with or without acidosis and alkalosis on cellular uptake of lipophilic
statin
Drug binding to plasma lipoproteins has been suggested to affect the blood-tissue partitioning
of lipophilic compounds, resulting in alterations in the pharmacological activity and/or potential
toxicity of these molecules (Wasan et al., 2008). In this study, the association of simvastatin with
plasma lipoproteins, particularly TRL and LDL, has enhanced the cellular uptake of lipophilic statin
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by C2C12 cells (Fig. 3 and 4). The partitioning of lipophilic statin from plasma lipoproteins to the
cells seems to be mediated by LPL. This enzyme is responsible for the intravascular hydrolysis of
triglycerides within lipoproteins into fatty acids and monoacylglycerol. It also regulates the cellular
uptake of fatty acids and cholesterol and controls the transport and internalisation of lipoprotein
particles by peripheral tissues by enhancing their binding to lipoprotein receptors (Obunike et al.,
1994; Rumsey et al., 1992). Statin uptake from plasma lipoproteins could be of a particular
importance when skeletal muscle tissue highly expresses LPL. Several conditions have been reported
to increase LPL expression in human skeletal muscle cells, such as chronic exercise, fibrate therapy
and fasting (Yokoyama et al., 2007). These conditions could increase the risk of statin-induced
myopathy by increasing the muscle uptake of simvastatin via the above-mentioned mechanism.
Indeed, the majority of professional athletes were found to be intolerant to most of the available
statins (Sinzinger and O'Grady, 2004). This group of population is known to have increased muscle
LPL expression (Herbert et al., 1984).
The extent of simvastatin uptake by C2C12 cells was partially proportional to the activity of
LPL in these cells. More simvastatin was taken up by cells that have higher LPL activity (mLPL ≈ 
hLPL > empty) (Fig. 3 and 4). Our results are in agreement with previous studies that demonstrated an
increase in the uptake of lipoprotein-associated compounds by tissues in the presence of LPL
(Nakamura et al., 1998; Sattler et al., 1996; Traber et al., 1985). The enhancement of simvastatin
uptake by C2C12 cells that have high LPL activity could be attributed to the higher triglyceride
hydrolysis rates (Traber et al., 1985), and the bridging function of the enzyme between lipoprotein-
drug complex and muscle cells (Sattler et al., 1996).
More simvastatin was found to be taken up by C2C12 cells when treated with simvastatin-
loaded LDL compared to simvastatin-loaded TRL. This process could be of clinical significance since
statin therapy has been shown to induce upregulation of LDL receptors in the skeletal muscle cells
(Yokoyama et al., 2007), resulting in an increased uptake of simvastatin-associated LDL by muscle
cells via LPL-mediated mechanism.
The cellular uptake of simvastatin by C2C12 cells was found to be strongly affected by the pH
levels of the culture medium. Higher simvastatin uptake was observed at acidic pH compared to
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physiological and alkaline pH. These results are in agreement with our previous observations that
showed higher cellular uptake of statins at acidic conditions compared to physiological and alkaline
environment (Taha et al., 2016).
4.4. Effect of hyperlipidaemia with or without acidosis and alkalosis on cytotoxicity of simvastatin
In the present study, the higher cytotoxicity of simvastatin observed in the presence of elevated
plasma lipoprotein levels are linked to drug association with TRL and LDL. These lipoprotein
fractions can serve as carriers for lipophilic statins and have been shown to increase simvastatin
uptake by muscle cells (Fig. 3 and 4).
In accordance with the uptake studies, the cytotoxicity profile of simvastatin-lipoprotein
complex in C2C12 cells was found to be proportional to the activity of LPL in these cells. Higher
cytotoxicity was observed in cells that have higher LPL enzyme activity (mLPL > hLPL > empty)
(Fig. 6 and 7). The effect of simvastatin association with plasma lipoproteins on the cytotoxicity was
further augmented when the skeletal muscle cells were maintained at acidic pH compared to
physiological and alkaline pH. The higher cytotoxicity of simvastatin under acidic conditions could be
attributed to the greater proportions of the lactone form of simvastatin that are associated with plasma
lipoprotein fractions. This lipophilic lactone from has higher ability to cross the cell membranes of
muscle cells and achieve high intracellular concentrations. On the other hand, the low cytotoxicity
observed under alkaline conditions is due to the low levels of the lactone form recovered within the
lipoprotein fractions under these conditions, resulting in lower intracellular concentrations of
simvastatin (Taha et al., 2016).
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5. Conclusions
This study demonstrated that hyperlipidaemia enhanced the association of simvastatin with the
non-polar plasma lipoprotein fractions such as TRL and LDL. This association contributed to
increased cellular uptake of this lipophilic statin by skeletal muscle cells resulting in a high local
intracellular concentration of simvastatin through LPL-mediated process. Moreover, the high
intracellular concentrations of simvastatin induced significantly higher myotoxicity compared to
normolipidaemic conditions. The coincidence of acidosis with hyperlipidaemia further augmented the
myotoxicity of this lipophilic statin. Acidic pH enhanced the association of simvastatin with plasma
lipoproteins by minimising the conversion of lipophilic lactone form to the hydrophilic hydroxy acid.
As a result, the intracellular concentrations of simvastatin in muscle cell line, as well as myotoxicity
were increased. The potential clinical significance of these results is that hyperlipidaemia, especially
when combined with acidosis, requires extra caution and monitoring by clinicians who should follow
a conservative approach when prescribing lipophilic statins to these patients. Hydrophilic rather than
lipophilic statins could be a preferable choice in patients that are prone to hyperlipidaemia with or
without acidosis.
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Figure legends
Fig. 1. Association of statins with human chylomicrons at different pH levels. Only simvastatin
lactone showed a considerable association with human chylomicrons while other statins (simvastatin
hydroxy acid, pravastatin lactone and pravastatin hydroxy acid) did not showed a detectable
association at any pH level. Results are presented as box and whiskers, (n=6). Data were analysed by
one-way ANOVA followed by Tukey’s post hoc test, **p < 001.
Fig. 2. Distribution of simvastatin lactone into different lipoprotein fractions from hyperlipidaemic
and normolipidaemic plasma. Simvastatin lactone was incubated with hyperlipidaemic or
normolipidaemic plasma at 37oC over physiological, acidic, and alkaline pH with constant mixing for
1 h. Lipoprotein fractions were separated by density gradient ultracentrifugation and the total amount
of simvastatin (both acid and lactone forms) recovered from each fraction were presented as
percentage of the initial amount of simvastatin lactone applied into plasma samples. Data are
presented as mean ± SE, (n=5). Statistical analysis was performed by two-way ANOVA followed by
Fisher's LSD post hoc test, *p < 0.05, **p < 001, ***p < 0.001. Red straight lines denote differences
in % of simvastatin recovered in lipoprotein fractions from hyperlipidaemic and normolipidaemic
plasmas. Black arched lines denote differences in simvastatin association within individual lipoprotein
fraction as a function of pH changes.
Fig. 3. Total simvastatin uptake by undifferentiated and differentiated C2C12 cells overexpressing
mLPL, hLPL, and control cells transfected with empty vector after 3 h of incubation with simvastatin
either loaded into triglyceride-rich lipoproteins or applied directly in solution. Data are presented as
mean ± SE, (n=5). Statistical analysis was performed by two-way ANOVA followed by Fisher's LSD
post hoc test, *p < 0.05, **p < 001, ***p < 0.001. Red straight lines denote differences in simvastatin
uptake between cells treated with SV-TRL and SV-Sol. Black arched lines denote differences in
simvastatin uptake by cells maintained at different pH.
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Fig. 4. Total simvastatin uptake by undifferentiated and differentiated C2C12 cells overexpressing
mLPL, hLPL, and control cells transfected with empty vector after 3 h of incubation with simvastatin
either loaded into low-density lipoprotein fraction or applied directly in solution. Data are presented
as mean ± SE, (n=5). Statistical analysis was done by two-way ANOVA followed by Fisher's LSD
post hoc test, *p < 0.05, **p < 001, ***p < 0.001. Red straight lines denote differences in simvastatin
uptake between cells treated with SV-LDL and SV-Sol. Black arched lines denote differences in
simvastatin uptake by cells maintained at different pH.
Fig. 5. Lipoprotein lipase activity in undifferentiated and differentiated C2C12 cells overexpressing
mLPL, hLPL, and control cells transfected with empty vector. Data are presented as mean ± SE,
(n=3). Statistical analysis was done by two-way ANOVA followed by Fisher's LSD post hoc test,
***p < 0.001.
Fig. 6. MTT assay of undifferentiated and differentiated C2C12 cells overexpressing mLPL, hLPL,
and control cells transfected with empty vector following treatment with simvastatin either loaded into
triglyceride-rich lipoproteins or applied directly in solution at different pH. Data are presented as
mean ± SE of 3 experiments, 8 replicate per experiment. The IC50 values are listed on graphs, when
applicable, and were derived by computing dose-response curves using a 4-parameter, variable slope
fit in GraphPad Prism. Statistical analysis was performed by two-way ANOVA followed by Fisher's
LSD post hoc test, aSignificant difference from SV-Sol (p < 0.001); bSignificant difference from pH
7.4 (p < 0.001); cSignificant difference from pH 7.4 (p < 0.01); dSignificant difference from hLPL (p <
0.001); eSignificant difference from mLPL and hLPL (p < 0.001); fSignificant difference from hLPL
(p < 0.05).
Fig. 7. MTT assay of undifferentiated and differentiated C2C12 cells overexpressing mLPL, hLPL,
and control cells transfected with empty vector following treatment with simvastatin either loaded into
low-density lipoprotein fraction or applied directly in solution at different pH. Data are presented as
mean ± SE of 3 experiments, 8 replicates per experiment. The IC50 values are listed on graphs, when
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applicable, and were derived by computing dose-response curves using a 4-parameter, variable slope
fit in GraphPad Prism. Statistical analysis was done by two-way ANOVA followed by Fisher's LSD
post hoc test, aSignificant difference from SV-LDL (p < 0.001); bSignificant difference from mLPL
and hLPL (p < 0.001); cSignificant difference from pH 7.4 (p < 0.001); dSignificant difference from
hLPL (p < 0.001); eSignificant difference from pH 7.4 (p < 0.01); fSignificant difference from mLPL
(p < 0.001).
Fig. 8. Lactate dehydrogenase release assay of undifferentiated and differentiated C2C12 cells
overexpressing mLPL, hLPL, and control cells transfected with empty vector following treatment
with simvastatin either loaded into lipoprotein fractions or applied directly in solution at different pH.
Data are presented as mean ± SE, (n=6). Statistical analysis was performed by two-way ANOVA
followed by Fisher's LSD post hoc test, *p < 0.05, **p < 001, ***p < 0.001. Black arched lines denote
differences in LDH release between different cell types. Red straight lines denote differences in LDH
release from a single cell type maintained at different pH.
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LogD7.4 0.299879 4.69 1.34 2.79 -0.67
LogP - LogD7.4 -0.238127 -0.27 2.72 -1.08 2.02
PSA -0.00855215 72.83 104.06 93.06 124.29
H-acceptors -0.184359 5 6 6 7
FRB 0.0805226 7 11 7 11
Density 1.45337 1.11 1.13 1.18 1.21
Molar volume 0.00545912 376.5 383.9 341.7 349.1
H-donors 0.0823094 1 3 2 4
Constant -5.24138
Predicted association with chylomicrons
(%)
9.08% 0.24% 1.78% 0.04%
Abbreviations: Log D, distribution coefficient; Log P, partition coefficient; PSA, polar surface area;
H-acceptors, hydrogen-bond acceptors; FRB, freely rotatable bonds; H-donors, hydrogen-
bond donors.
3Supplementary Figure 1. Triglyceride content of individual lipoprotein fraction following
ultracentrifugation of hyperlipidaemic and normolipidaemic plasma samples of different pH. Results
are expressed as mean ± SE, (n=5). Statistical analysis was done by two-way ANOVA followed by
Fisher's LSD posthoc test, **p < 001, ***p < 0.001.
4Supplementary Figure 2. Cholesterol content of individual lipoprotein fraction following
ultracentrifugation of hyperlipidaemic and normolipidaemic plasma samples of different pH. Results
are expressed as mean ± SE, (n=5). Data were analysed by two-way ANOVA followed by Fisher's
LSD posthoc test, **p < 001, ***p < 0.001.
5Supplementary Figure 3. Correlation between the amount of simvastatin (SV) recovered from
individual lipoprotein fraction and the triglyceride content of the lipoprotein following incubation of
hyperlipidaemic (HL) and normolipidaemic (NL) plasma of different pH with simvastatin lactone.
Correlation was determined by Pearson’s correlation coefficient (r), **p < 0.01.
6Supplementary Figure 4. Correlation between the amount of simvastatin (SV) recovered from
individual lipoprotein fraction and the cholesterol content of the lipoprotein following incubation of
hyperlipidaemic (HL) and normolipidaemic (NL) plasma of different pH with simvastatin lactone.
Correlation was determined by Pearson’s correlation coefficient (r), **p < 0.01.
7Supplementary Figure 5. Percentage of simvastatin lactone (SVL) and corresponding hydroxy acid
form (SVA) recovered from individual lipoprotein fraction of hyperlipidaemic plasma. Results are
expressed as mean ± SE, (n=5). Statistical analysis was done by two-way ANOVA followed by
Fisher's LSD posthoc test, *p < 0.05, **p < 001, ***p < 0.001.
8Supplementary Figure 6. Percentage of simvastatin lactone (SVL) and corresponding hydroxy acid
form (SVA) recovered from individual lipoprotein fraction of normolipidaemic plasma. Results are
expressed as mean ± SE, (n=5). Statistical analysis was done by two-way ANOVA followed by
Fisher's LSD posthoc test, *p < 0.05, **p < 001, ***p < 0.001.
9Supplementary Figure 7. Fold-change of total simvastatin uptake by undifferentiated and
differentiated C2C12 cells overexpressing mLPL, hLPL, and control cells transfected with empty
vector after 3 h of incubation with simvastatin either loaded into triglyceride-rich lipoproteins (SV-
TRL) or applied directly in solution (SV-Sol). Data are presented as mean ± SE, (n=5). Statistical
analysis was performed by two-way ANOVA followed by Fisher's LSD post hoc test, *p < 0.05, **p
< 001, ***p < 0.001.
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Supplementary Figure 8. Fold-change of total simvastatin uptake by undifferentiated and
differentiated C2C12 cells overexpressing mLPL, hLPL, and control cells transfected with empty
vector after 3 h of incubation with simvastatin either loaded into low-density lipoprotein fraction (SV-
LDL) or applied directly in solution (SV-Sol). Data are presented as mean ± SE, (n=5). Statistical
analysis was performed by two-way ANOVA followed by Fisher's LSD post hoc test, *p < 0.05, **p
< 001, ***p < 0.001.
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Supplementary Figure 9. Fold-change of lipoprotein lipase activity in undifferentiated and
differentiated C2C12 cells overexpressing mLPL, hLPL, and control cells transfected with empty
vector. Data are presented as mean ± SE, (n=3). Statistical analysis was done by two-way ANOVA
followed by Fisher's LSD post hoc test, *p < 0.05, **p < 001, ***p < 0.001.
